BioNTech SE
BNTX · NASDAQ
Company research
BioNTech SE (NASDAQ: BNTX) is a German multinational biotechnology company headquartered in Mainz, Germany, founded in 2008 and focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases. The company leverages a multi-technology innovation engine encompassing mRNA-based therapies, CAR-T cell therapies, antibody-drug conjugates, checkpoint immunomodulators, and small molecules to build a broad and diversified oncology and infectious disease pipeline. BioNTech gained global recognition through its landmark partnership with Pfizer to develop Comirnaty, the first approved mRNA-based COVID-19 vaccine, which is now available in over 180 countries and commands more than 50% market share in its segment. With a market capitalization of approximately $23.8 billion, a robust cash position, and strategic collaborations with major pharmaceutical partners including Pfizer, Genentech, Sanofi, Genmab, and Regeneron, BioNTech is actively transitioning from a single-product company into a diversified, multi-product immunotherapy leader with several late-stage oncology candidates advancing through clinical development.
Research reports
ChartMill · May 4, 2026BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides
This ChartMill article analyzes BioNTech’s Q1 2026 results, highlighting that a revenue miss and widened net loss overshadow progress in the oncology pipeline and trigger a share price decline of around 3%, framing the quarter as fundamentally disappointing. The discussion situates the performance within broader cost-cut initiatives and market reaction, offering a clearly negative near-term outlook without specifying a formal rating or price target.
Ultra Stock Analysis Pro · March 13, 2026BioNTech SE (BNTX) - ANALYST REPORT - Ultra Stock Analysis ProThis comprehensive PDF analyst report assigns BNTX a HOLD rating and recommends waiting for a stronger technical “confluence” signal before entering, despite an estimated 42.1% upside to the consensus target price of 129.61 over a 6–12 month horizon. It combines detailed technical backtesting, analyst consensus data, valuation and profitability metrics, institutional ownership, news sentiment, and a structured risk assessment, concluding that mixed fundamentals and high volatility justify a cautious, neutral stance with defined stop-loss parameters.